- Home
- REBN vs NRXS Comparison
REBN vs NRXS Comparison
Compare REBN & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- NRXS
- Stock Information
- Founded
- REBN 2015
- NRXS 2011
- Country
- REBN United States
- NRXS United States
- Employees
- REBN N/A
- NRXS N/A
- Industry
- REBN Restaurants
- NRXS
- Sector
- REBN Consumer Discretionary
- NRXS
- Exchange
- REBN Nasdaq
- NRXS Nasdaq
- Market Cap
- REBN 12.8M
- NRXS 13.0M
- IPO Year
- REBN 2022
- NRXS 2023
- Fundamental
- Price
- REBN $2.58
- NRXS $2.43
- Analyst Decision
- REBN
- NRXS Strong Buy
- Analyst Count
- REBN 0
- NRXS 1
- Target Price
- REBN N/A
- NRXS $7.00
- AVG Volume (30 Days)
- REBN 85.6K
- NRXS 61.1K
- Earning Date
- REBN 08-18-2025
- NRXS 08-12-2025
- Dividend Yield
- REBN N/A
- NRXS N/A
- EPS Growth
- REBN N/A
- NRXS N/A
- EPS
- REBN N/A
- NRXS N/A
- Revenue
- REBN $6,103,732.00
- NRXS $2,934,945.00
- Revenue This Year
- REBN $335.98
- NRXS $73.05
- Revenue Next Year
- REBN N/A
- NRXS $130.42
- P/E Ratio
- REBN N/A
- NRXS N/A
- Revenue Growth
- REBN 3.38
- NRXS 27.52
- 52 Week Low
- REBN $1.03
- NRXS $1.33
- 52 Week High
- REBN $8.30
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- REBN 43.78
- NRXS 42.05
- Support Level
- REBN $2.50
- NRXS $2.41
- Resistance Level
- REBN $2.84
- NRXS $2.64
- Average True Range (ATR)
- REBN 0.20
- NRXS 0.11
- MACD
- REBN -0.02
- NRXS -0.03
- Stochastic Oscillator
- REBN 14.18
- NRXS 5.77
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).